• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Ophthalmic topical formulation of bosentan. The present invention relates to an ophthalmic topical formulation of bosentan, preferably in the form of an aqueous solution. It also relates to the use of an ophthalmic topical formulation comprising bosentan as an active principle for the prevention and/or treatment of the neurodegeneration of the retina induced by diabetes and/or aging. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2584534A1
    申请号:ES201530409
    申请日:2015-03-27
    公开日:2016-09-28
    发明作者:Vicente DURAN MUIÑOS；Marta GUERRERO MARTÍNEZ；Cristina Hernández Pascual；José Bruno MONTORO RONSANO；Rafael Simó Canonge；José María SUÑÉ NEGRE；José Ramón TICÓ GRAU
    申请人:Retinset S L；Retinset Sl；
    IPC主号:
    专利说明:

    image 1
    image2
    image3
    image4
    image5
    image6
    its salts, such as bosentan monohydrate, or bosentan sodium salt. In the formulation of the invention, bosentan monohydrate is preferably used.
    In the formulation of the invention, bosentan, expressed as bosentan, is generally comprised between 0.1% and 5% in (w / v) with respect to the total volume of the formulation, preferably between 0.2% and 2% and even more preferably between 0.5% and 1%. In the case of using bosentan in the form of monohydrate or another hydrate, or in the form of sodium salt or another salt, the person skilled in the art can easily calculate the corresponding amounts.
    In the formulation of the invention, the active ingredient can be found incorporated in the form of microparticles, nanoparticles, liposomes or niosomes.
    In a preferred embodiment, the formulation of the invention comprises bosentan in combination with another active ingredient such as, for example, corticosteroids, prostaglandins, growth factors, anti-VEGF factors, or peptides. Preferably bosentan is used in combination with growth factors.
    The wetting solvent
    The formulation of the invention comprises a pharmaceutically acceptable humectant solvent selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and mixtures thereof.
    A humectant solvent, in the context of the invention, is a compound that has solvent and humectant properties.
    Among them is polyethylene glycol (PEG), a name that designates a wide family of polymers with different molecular weights, obtained by condensation of ethylene oxide and water in the presence of a catalyst. The formula of said polymers can be represented as H (OCH2CH2) nOH, where n represents the average number of oxyethylene groups.
    PEG is widely used in pharmaceutical compositions, including parenteral, topical, ophthalmic, oral, and rectal formulations, since it is a stable compound that is essentially non-irritating to the skin. It is also a hydrophilic compound, easily soluble in water.
    The appropriate PEG for use in the formulation of the invention can have a molecular weight between 300 and 35,000, preferably between 600 and 20,000, more preferably between 1000 and 8000, even more preferably between 3000 and 6000, and still more preferably about 4000 The different PEGs are designated by a number that accompanies the term PEG. Thus, PEG 200 means a PEG having an approximate average molecular weight of 200. Depending on the molecular weight, the PEG is liquid or solid. Thus, PEGs with an average molecular weight of up to 800 are liquid at room temperature, PEG 1000 melts at a temperature between 37º C and 40º C, and PEG 4000 melts between 50º C and 58º C. The higher oxide content of ethylene, the higher the melting point of PEG.
    PEG can be obtained commercially, for example, under the name Carbowax® supplied by the company Dow Chemical.
    Propylene glycol is a colorless, transparent, viscous, and practically odorless liquid, which is obtained by hydrolysis of propylene oxide.
    Glycerin is also a colorless, transparent, viscous and practically odorless liquid, with a slight sweet taste.
    In the formulation of the invention, PEG and / or propylene glycol, more preferably PEG 4000 and / or propylene glycol, are used as the wetting solvent, and even more preferably it is PEG 4000.
    In the formulation of the invention the content of the wetting solvent is usually between 1% and 49% in (w / v) with respect to the total volume of the formulation, preferably between 5% and 40%, more preferably between 10% and 30%, and even more preferably between 15% and 25%.
    The pH regulating system
    The formulation of the invention comprises a pharmaceutically regulatory system.
    image7
    Other components
    The ophthalmic topical formulation of the invention may include other components such as, for example, surfactants, cosolvents, viscosizers, preservatives, isotonic agents, isoosmotizing agents, absorption enhancers of the active ingredient, mucoadhesive polymers, non-mucoadhesive polymers, chelants, stabilizers, antioxidants , and mixtures thereof.
    Among the surfactants there may be mentioned, for example, polyethoxylated glycerides, polysorbates, poloxamers, sodium lauryl sulfate, phospholipids, such as phosphatidylcholine or phosphatidylglycerol and its derivatives, polyoxyethylene hydrogenated castor oil, polyoxyethylene dihydrated fatty acids, mixtures of triglycerinated dihydrates, mixtures of triglycerides, triglycerides of optionally polyoxyethylene fatty acids, and mixtures thereof.
    Among the cosolvents or solubilizers there may be mentioned, for example, polyoxyethylene derivatives of castor oil, polyoxyethylene stearates, polyethylene glycol, polysorbates, poloxamers, glycerin, C6-C10 medium chain triglycerides, and mixtures thereof.
    Among the viscosifying agents there may be mentioned, for example, polyvinyl alcohol, methyl cellulose, hydroxypropyl methylcellulose, carbomers, polyethylene glycol, and mixtures thereof.
    Among the preservatives, for example, benzalkonium chloride, boric acid, benzoic acid, C1-C4 alkyl chain esters of p-hydroxybenzoic acid, chlorobutanol, benzyl alcohol, organometallic derivatives of mercury, polyquartenium as polyquaternium 1, and mixtures may be mentioned. thereof.
    Among the isotonizing and isoosmotizing agents there may be mentioned, for example, inorganic salts such as sodium chloride, dextrose, trehalose, mannitol, amino acids, and mixtures thereof.
    Among the absorption enhancers of the active ingredient may be mentioned, for example, saponin, fatty acid, C1-C4 alkyl chain ester of a fatty acid, pyrrolidone, polyvinylpyrrolidone, pyruvic acid, pyroglutamic acid, and mixtures thereof.
    image8
    image9
    image10
    of the invention was administered directly to the eyes of diabetic mice (db / db). These animals have a mutation in the gene that codes for the leptin receptor and represent an obesity-induced type 2 diabetes model, as described in, for example, Duval et al., Characterization of db / db mice for efficacy / safety pharmacology assessment of antidiabetic drugs, Safety Pharmacology Society Annual Meeting, Phoenix, 2012.
    The formulation of the invention was administered for a period of 14 days, twice a day, and after the test period a lower glial activation and a reduction of apoptosis was observed in all the retinal layers of animals treated with bosentan .
    Glial activation (or reactive gliosis) is the inflammatory response of glia cells (neuron support cells) that occurs when there is a noxa (for example, diabetes) that damages the retina. Neural death due to apoptosis represents the final phase of the neurodegenerative process of the retina.
    This means that topical administration of bosentan prevents neuroinflammation of the retina and neuronal death induced by diabetes.
    Surprisingly, the topical ophthalmic formulation of the invention allows bosentan to penetrate the retina through the ophthalmic mucosa and exert its therapeutic action to prevent and / or treat retinal neurodegeneration.
    Some examples are included below to illustrate the present invention, although they should not be considered as limiting thereof.
    Examples
    Data corresponding to animal tests are presented as mean ± standard deviation. Comparisons of continuous variables were made using the paired and unpaired Student t-test. The comparisons of the categorical variables were made using the Fisher test. The levels of statistical significance were set at p <0.05.
    Example 1: Ophthalmic topical formulation
    In 75 mL of deionized water, 20 g of polyethylene glycol 4000 were dissolved by magnetic stirring, allowed to stir until completely dissolved. Then you
    5 added 1.5 g of tromethamine and stirred for 15 minutes, checking its total dissolution. Then an amount of bosentan monohydrate, equivalent to 0.5 g of bosentan, was added and left under stirring for 15 minutes, checking its total dissolution. Then 2 g of glycine and 1 g of boric acid were added and allowed to stir until completely dissolved.
    10 The solution was flush to 100 mL by adding deionized water in sufficient quantity. The solution was filtered with filter paper, and a colorless and transparent solution was obtained, with a pH of 8.06. The solution was packaged in eye dropper bottles with a volume of 5 mL.
    15 Examples 2 to 7: Topical ophthalmic compositions
    Following a procedure analogous to that of Example 1, the topical ophthalmic compositions described in Table 1 were prepared:
    20 TABLE 1
    Component Examples
    2 34567
    Bosentan 0.50.50.50.50.50.5
    PEG 4000 twenty-twentytwentytwentyfifteen
    Propylene glycol -twenty---7.5
    Trometamol  -1.5---1.5
    Arginine 1.5-----
    Lysine ---1.5--
    Methylglucamine ----1.5-
    TO. boric oneone-oneoneone
    Glycine 22-222
    TO. citric / sodium citrate --c.s.p. pH 4-8.5---
    Water c.s.p. 100100100100100100
    The amounts of the components are expressed in grams, and the amount of water refers to 100 mL. 5 In all cases, clear and colorless compositions with a pH between 5 and 8.5 were obtained. Examples 8 to 19: Combination of excipients 10 Following a procedure analogous to that of Example 1, the topical ophthalmic compositions described in Tables 2 and 3 were prepared: TABLE 2
    Component Examples
    8 910eleven1213
    Bosentan 0.50.50.50.50.50.5
    PEG 400 twenty---1412
    PEG 800 -twenty----
    PEG 1000 --twenty---
    PEG 4000 ---twenty--
    Propylene glycol ----78
    Trometamol 0.20.5one50.20.5
    Arginine 50.20.5one50.2
    Lysine  one50.20.5one5
    Methylglucamine 0.5one0.50.20.5one
    Water c.s.p. 100100100100100100
    TABLE 3
    Component Examples
    14 fifteen16171819
    Bosentan 0.50.50.50.50.50.5
    PEG 400 108----
    Glycerin  -681012
    Propylene glycol 10121412108
    Trometamol  one50.20.5one5
    Arginine 0.5one50.20.5one
    Lysine 0.20.5one50.20.5
    Methylglucamine 0.50.20.5one0.50.2
    Water c.s.p. 100100100100100100
    5 Examples 20 to 24: Lipophilic ointments Following a standard procedure, ophthalmic topical compositions were prepared in the form of lipophilic ointments described in Table 4: 10.
    image11
    Examples 30 to 34: Hydrogels Following a standard procedure, the topical hydrogel-shaped ophthalmic compositions that are described in Table 6 were prepared: TABLE 6
    Component Examples
    30 3132333. 4
    Bosentan 0.50.50.50.50.5
    HPMC 5 KM one232one
    Arginine 1.51.5-1.51.5
    Trometamol  1.5-1.5--
    Glycine 22-22
    TO. citric / sodium citrate c.s.p. pH = 8.5c.s.p. pH = 7c.s.p. pH = 7.5c.s.p. pH = 8c.s.p. pH = 8.5
    Water c.s.p. 100gc.s.p. 100gc.s.p. 100gc.s.p. 100gc.s.p. 100g
    Example 35: Topical ophthalmic solution with bosentan nanoparticles
    The nanoparticles were prepared by the solvent evaporation technique.
    A solution of 120 mg of 50:50 PLGA in 60 mL of ethyl acetate was prepared. An aqueous solution of 50 mL of water with 12 mg of bosentan monohydrate and 0.5 mg of polyvinyl alcohol was incorporated under turboagitation. The resulting mixture is
    15 left under continuous stirring and under vacuum for 2 hours. Then, the resulting preparation was ultracentrifuged and washed with water three times, to separate the nanoparticles from the medium.
    image12
    image13
    image14
    image15
    image16
    权利要求:
    Claims (1)
    [1]
    image 1
    image2
    image3
    类似技术:
    公开号 | 公开日 | 专利标题
    ES2784229T3|2020-09-23|Compositions and procedures for the treatment of eye inflammation and pain
    ES2532595T3|2015-03-30|Pharmaceutical composition containing an encapsulated statin nanoparticle
    US8759403B2|2014-06-24|Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions
    ES2719226T3|2019-07-09|Compositions comprising corticosteroid prodrugs such as dexamethasone palmitate for the treatment of eye disorders
    ES2673009T3|2018-06-19|Topical microemulsion delivery platform
    ES2369089T3|2011-11-25|WATERY OPTICAL DROPS WITH ACCELERATED INTRAOCULAR MIGRATION.
    ES2780182T3|2020-08-24|Macrogol 15-hydroxystearate formulations
    WO2013000909A1|2013-01-03|Topical ophthalmological pharmaceutical composition containing sorafenib
    JP2017512748A|2017-05-25|Ophthalmic topical pharmaceutical composition containing sunitinib
    EP2863888A1|2015-04-29|Topical ophthalmological pharmaceutical composition containing axitinib
    JP2015523995A|2015-08-20|Ophthalmic topical pharmaceutical composition containing pazopanib
    ES2540151B1|2016-02-29|Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use
    ES2584534A1|2016-09-28|Ophthalmic topical formulation of bosentan |
    ES2702578T3|2019-03-04|Treatment of chronic dermal inflammation with norketotifen
    WO2017190714A1|2017-11-09|Phenol compound and combination of same with a benzodiazepine fused to 1,4-dihydropyridine for treating diseases of the central nervous and vascular systems
    ES2371340T3|2011-12-30|PREPARED WATER LIQUIDS AND PREPARED PHOTOSTABLE WATER LIQUIDS.
    EP2863885A1|2015-04-29|Topical ophthalmological pharmaceutical composition containing cediranib
    JP2021512864A|2021-05-20|Parenteral preparation and its use
    ES2891306T3|2022-01-27|Combination of ibudilast and riluzole and methods of using them
    JP2021095420A|2021-06-24|Aqueous pharmaceutical composition containing epinastine or salt thereof
    ES2863701T3|2021-10-11|Dipeptidyl peptidase-4 inhibitors for topical ocular treatment of neurodegenerative retinal diseases
    ES2414557B1|2014-06-10|Aqueous composition of paracetamol for injection
    JP2019536769A|2019-12-19|Mucosal agent delivery
    ES2363965B1|2013-01-24|CAPSULES OF BETABLOCKING ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.
    ES2352296T3|2011-02-17|EMULSION OF OIL IN WATER THAT INCLUDES NSAIDS AND HALUROS OF AMMONIUM CUATERNARIOS.
    同族专利:
    公开号 | 公开日
    BR112017019792A2|2018-05-22|
    KR20170130443A|2017-11-28|
    US10716750B2|2020-07-21|
    JP6768780B2|2020-10-14|
    WO2016156639A1|2016-10-06|
    ES2584534B1|2017-03-13|
    US20180110728A1|2018-04-26|
    JP2018512452A|2018-05-17|
    CN107454841A|2017-12-08|
    MX2017012428A|2018-06-19|
    EP3275429A1|2018-01-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20030176356A1|2001-04-24|2003-09-18|University Of North Texas Health Science Center|Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma|CN106924190A|2015-12-30|2017-07-07|深圳翰宇药业股份有限公司|A kind of ACT-064992 microballoon and preparation method thereof|RU2086544C1|1991-06-13|1997-08-10|Хоффманн-Ля Рош АГ|Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity|
    US6770675B2|1997-03-17|2004-08-03|Novartis Ag|Compositions and methods for reducing ocular hypertension|
    JP4725699B2|2002-04-08|2011-07-13|ライオン株式会社|Ophthalmic composition and preservative for blending ophthalmic composition|
    HUE055815T2|2007-10-05|2021-12-28|Univ Wayne State|Dendrimers for sustained release of compounds|
    KR101805116B1|2007-12-04|2017-12-06|산텐 에스에이에스|Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders|
    US8821870B2|2008-07-18|2014-09-02|Allergan, Inc.|Method for treating atrophic age related macular degeneration|
    US9034830B2|2009-10-30|2015-05-19|Intratus, Inc.|Methods and compositions for sustained delivery of drugs|
    FR2961694B1|2010-06-29|2013-01-25|Thea Lab|POLYMERIC DELIVERY SYSTEM FOR NON-VISCOUS SOLUTION BASED ON PROSTAGLANDIN WITHOUT PRESERVATIVE|
    EP2567689A1|2011-09-12|2013-03-13|Visiotact Pharma|Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid|
    ES2884813T3|2013-03-13|2021-12-13|Buzzard Pharmaceuticals AB|Chimeric Cytokine Formulations for Ocular Administration|
    PL2968139T3|2013-03-14|2018-10-31|EyeCRO, LLC|Microemulsion topical delivery platform|
    CA2949954A1|2014-05-23|2015-11-26|Ocular Technologies Sarl|Topical formulations and uses thereof|CA3092861A1|2018-03-07|2019-09-12|Timber Pharmaceuticals, Inc.|Compositions and methods for treating cutaneous fibrosis|
    法律状态:
    2017-03-13| FG2A| Definitive protection|Ref document number: 2584534 Country of ref document: ES Kind code of ref document: B1 Effective date: 20170313 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201530409A|ES2584534B1|2015-03-27|2015-03-27|Bosentan ophthalmic topical formulation|ES201530409A| ES2584534B1|2015-03-27|2015-03-27|Bosentan ophthalmic topical formulation|
    EP16720451.0A| EP3275429A1|2015-03-27|2016-03-22|Topical ophthalmic formulation of endothelin receptor antagonists|
    KR1020177027527A| KR20170130443A|2015-03-27|2016-03-22|Topical formulation of endothelin receptor antagonist|
    MX2017012428A| MX2017012428A|2015-03-27|2016-03-22|Topical ophthalmic formulation of endothelin receptor antagonists.|
    PCT/ES2016/070197| WO2016156639A1|2015-03-27|2016-03-22|Topical ophthalmic formulation of endothelin receptor antagonists|
    CN201680018617.3A| CN107454841A|2015-03-27|2016-03-22|Topical ophthalmic of endothelin-receptor antagonists and application thereof|
    US15/561,922| US10716750B2|2015-03-27|2016-03-22|Topical ophthalmic formulations of endothelin receptor antagonists|
    JP2018500867A| JP6768780B2|2015-03-27|2016-03-22|Topical ophthalmic preparations of endothelin receptor antagonists and their use|
    BR112017019792A| BR112017019792A2|2015-03-27|2016-03-22|topical ophthalmic formulation and use thereof.|
    [返回顶部]